Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Symtuza vs. Separate Agents in Healthy Adults
NCT04661397Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration and Area Under the Analyte Concentration-time Curve from time Zero to Last Quantifiable time. Started Jan 2021; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04661397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661397.